B-cell tumor-associated antigens (CD19, CD20, CD22, CD37)

The target involves a specific set of B-cell lineage antigens—CD19, CD20, CD22, and CD37—that are targeted through a novel molecular mimicry approach. This therapeutic strategy utilizes EO2463, an 'off-the-shelf' immunotherapy comprising four synthetic long peptides derived from the human gut microbiome, known as OncoMimics (Source: Enterome, 2021). These peptides are selected for their high structural homology to the aforementioned B-cell markers. In patients who are HLA-A2 positive, these mimic peptides are presented by MHC class I molecules, triggering the activation and expansion of pre-existing memory T cells originally primed by the microbiome (Source: ClinicalTrials.gov, NCT04663139). These activated T cells then cross-react with and eliminate malignant B cells expressing the native human antigens. This multi-antigen targeting approach is designed to treat B-cell malignancies, such as follicular lymphoma and marginal zone lymphoma, while minimizing the risk of tumor escape through antigen loss (Source: Alouani et al., 2021). The biological function of these antigens is centered on B-cell development and signaling, and their role in disease is primarily as markers for hematologic cancers. Safety considerations include the expected depletion of healthy B cells, which may lead to hypogammaglobulinemia and an increased risk of infection.

Other names

OncoMimicsEO2463 target antigensB-cell lineage antigensCD19/CD20/CD22/CD37

Induction of a cytotoxic T-cell response through molecular mimicry, where microbiome-derived peptides presented on HLA-A2 activate memory T cells to target CD19, CD20, CD22, and CD37 on B cells.